Verition Fund Management LLC Galectin Therapeutics Inc Transaction History

Verition Fund Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.61 - $5.0 $53,456 - $74,040	-14,808 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.86 - $6.02 $57,158 - $89,144	14,808 New	14,808 $76,000
Q2 2018 Aug 15, 2018	SELL	$3.16 - $9.16 $32,216 - $93,386	-10,195 Closed	0 $0
Q1 2018 May 16, 2018	BUY	$3.78 - $5.97 $38,537 - $60,864	10,195 New	10,195 $48,000

9.36M

982K

2.7K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $150M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.